ArticlePreventive medicine reports2026
Integrating human papillomavirus (HPV) vaccine into China's National Immunization Program: global lessons and strategic considerations.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To review global evidence on human papillomavirus (HPV) vaccine introduction and delivery strategies, and derive actionable lessons for China's ongoing national rollout following its integration of HPV vaccine into the national immunization program in November 2025. Methods: This is an analytical essay that synthesises published evidence on HPV vaccination programs worldwide, with a focus on delivery strategies, coverage outcomes, and implementation barriers. Literature was identified through PubMed and WHO databases for the period 2012-2026. No primary data collection was conducted. Results: As of June 2020, 107 of 194 WHO member states (55%) had introduced HPV vaccination, yet only 15% of girls worldwide completing the series. School-based delivery with grade-based targeting achieves highest coverage (e.g., Rwanda >90%), and mixed models (school-based with facility-based catch-up) represent best practice. Key barriers include vaccine hesitancy, logistical complexity, weak data systems, and policy design. In China, enablers include domestic vaccine production capacity, centralized governance, the nine-year compulsory education system, and established school-based health programs; major challenges include parental hesitancy, regional disparities, and social media misinformation. Conclusions: Drawing on global experience, China should leverage its existing health and education infrastructure to implement the current two-dose schedule effectively, strengthen multi-level communication strategies, and proactively manage vaccine confidence to achieve high and equitable coverage, contributing to global cervical cancer elimination goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.